Creekmur Asset Management LLC Grows Position in Quest Diagnostics Incorporated (NYSE:DGX)

Creekmur Asset Management LLC lifted its position in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 12,038.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,578 shares of the medical research company's stock after buying an additional 1,565 shares during the period. Creekmur Asset Management LLC's holdings in Quest Diagnostics were worth $267,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Kingsview Wealth Management LLC purchased a new position in Quest Diagnostics during the first quarter valued at $2,908,000. Ascent Wealth Partners LLC lifted its position in shares of Quest Diagnostics by 49.5% in the first quarter. Ascent Wealth Partners LLC now owns 6,011 shares of the medical research company's stock worth $1,017,000 after buying an additional 1,990 shares in the last quarter. Legacy Capital Wealth Partners LLC purchased a new stake in shares of Quest Diagnostics in the first quarter worth about $414,000. Cullen Frost Bankers Inc. increased its stake in Quest Diagnostics by 5.9% during the first quarter. Cullen Frost Bankers Inc. now owns 1,059 shares of the medical research company's stock worth $179,000 after acquiring an additional 59 shares during the last quarter. Finally, Bryn Mawr Capital Management LLC bought a new stake in Quest Diagnostics during the first quarter worth approximately $337,000. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Quest Diagnostics

In other Quest Diagnostics news, SVP Mark E. Delaney sold 874 shares of the stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $175.72, for a total value of $153,579.28. Following the sale, the senior vice president owned 8,372 shares of the company's stock, valued at $1,471,127.84. This trade represents a 9.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on DGX shares. Piper Sandler increased their price objective on Quest Diagnostics from $180.00 to $200.00 and gave the stock a "neutral" rating in a research note on Monday, April 28th. Truist Financial increased their price objective on Quest Diagnostics from $182.00 to $190.00 and gave the company a "hold" rating in a report on Wednesday, April 23rd. Wall Street Zen lowered Quest Diagnostics from a "buy" rating to a "hold" rating in a report on Saturday, June 7th. Mizuho increased their price objective on Quest Diagnostics from $178.00 to $189.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Finally, Robert W. Baird increased their price objective on Quest Diagnostics from $191.00 to $194.00 and gave the company an "outperform" rating in a report on Wednesday, April 23rd. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $186.07.

Quest Diagnostics Trading Down 0.8%

NYSE:DGX traded down $1.39 during trading hours on Friday, hitting $166.79. The company had a trading volume of 1,557,274 shares, compared to its average volume of 1,003,691. The company has a current ratio of 1.44, a quick ratio of 1.31 and a debt-to-equity ratio of 0.84. The company has a 50-day moving average of $174.95 and a 200 day moving average of $169.08. The company has a market cap of $18.62 billion, a P/E ratio of 21.09, a P/E/G ratio of 2.33 and a beta of 0.49. Quest Diagnostics Incorporated has a 1 year low of $137.71 and a 1 year high of $182.38.

Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The medical research company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.15 by $0.06. Quest Diagnostics had a return on equity of 15.11% and a net margin of 8.81%. The business had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.63 billion. Sell-side analysts expect that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, July 21st. Shareholders of record on Monday, July 7th will be given a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 1.92%. The ex-dividend date of this dividend is Monday, July 7th. Quest Diagnostics's dividend payout ratio is currently 40.46%.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.